Telesis Bio Inc. announced continued expansion of the BioXp Select product line, releasing two novel kits to enable DNA amplification and scale-up. The BioXp Select DNA Cloning and Amplification Kit and the BioXp Select Plasmid Amplification Kit enable on-demand and automated synthesis and amplification of transfection-scale DNA beginning from the customers own DNA fragments or plasmid DNA, overnight and at the push of a button. This is expected to enable researchers to optimize their discovery workflows by reducing the time and steps for cloning and scale-up of DNA required for their testing and analysis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.45 USD | -2.54% | -23.33% | -51.96% |
05-09 | Earnings Flash (TBIO) TELESIS BIO Reports Q1 Revenue $3.4M | MT |
05-09 | Telesis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.96% | 5.77M | |
+10.03% | 223B | |
+13.59% | 195B | |
+20.01% | 144B | |
+30.83% | 111B | |
+2.05% | 65.01B | |
+15.38% | 53.02B | |
+3.96% | 50.45B | |
+8.37% | 44.15B | |
+3.27% | 36.45B |
- Stock Market
- Equities
- TBIO Stock
- News Telesis Bio, Inc.
- Telesis Bio Inc. Releases Bioxp® Select Kits to Enable DNA Amplification and Scale-Up